Clinical Trial Update: ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial for ARALAST NP in COPD with Alpha1-antitrypsin deficiency has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Aralast NP (alpha1-antitrypsin)

Snippet

Sponsor: Shire | Conditions: Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency | Phase 4 | Status: WITHDRAWN